Core Insights - Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, exceeding the Zacks Consensus Estimate by 350% and showing a year-over-year increase of 33.3% [1][8] - The company’s total revenues for Q4 2025 were $209.8 million, a slight decline of 0.4% year over year, but still surpassing the Zacks Consensus Estimate by 1.07% [3][8] - MYGN's shares surged by 21.7% in after-hours trading following the earnings announcement [3][8] Financial Performance - For the full year 2025, adjusted earnings were 6 cents per share, down from 14 cents in the previous year [2] - The gross margin for Q4 fell by 168 basis points to 70%, attributed to a 5.5% increase in the cost of revenues [5][8] - Research and development expenses decreased by 14.1% year over year to $25.5 million, while SG&A expenses dropped by 16.4% to $55.6 million [5] Revenue Breakdown - In Q4, Hereditary Cancer testing revenues increased by 3% year over year to $96.8 million, while Tumor Profiling testing revenues rose by 2% to $31.5 million [4] - Prenatal testing revenues remained flat at $44.9 million, and Mental Health revenues decreased by 10% to $36.6 million [4] Financial Position - At the end of Q4 2025, Myriad Genetics had cash and cash equivalents of $149.6 million, up from $102.4 million at the end of Q4 2024 [6] - Long-term debt increased to $119.9 million from $39.6 million at the end of Q4 2024 [6] - The cumulative net cash outflow from operating activities was $1.8 million, an improvement from an outflow of $8.7 million in the previous year [6] Future Guidance - Myriad Genetics expects 2026 revenues to be between $860 million and $880 million, with a Zacks Consensus Estimate of $867.5 million [9] - The company anticipates a full-year adjusted gross margin in the range of 68%-69% and adjusted EBITDA between $37 million and $49 million [9] Strategic Developments - The company is making progress in its cancer care continuum strategy, focusing on maintaining leadership in hereditary cancer testing while expanding into other cancer testing applications [10] - The newly launched expanded MyRisk panel has received positive market feedback, and the company is preparing to start commercial testing of PRECISE MRD for breast cancer [10]

Group 1 - The article does not provide any specific content related to a company or industry [1]